You are seeing these quotes based on previous browsing related to sectors such as
| Latest | Forecast | |
|---|---|---|
| Div Yield | 3.4% | 3.7% |
| Div Cover | 1.1 | 2.1 |
| Op Mrgn | 18.3% | 35.6% |
| ROCE | 39.3% |
| Latest | Forecast | |
|---|---|---|
| P/E | 25.8 | 1,293.9 |
| PEG | -0.9 | 0.1 |
| Price / Revenue | 3.8 | 3.9 |
| Price / Book value | 7.2 |
| Latest | Forecast | |
|---|---|---|
| Revenue | 2.5% | -8.7% |
| PBT | -23.3% | n/a |
| EPS | -27.3% | -11.0% |
| DPS | 9.7% | 1.7% |
| Year Ending | Revenue (€m) |
Pre-tax (€m) |
EPS | P/E | PEG | EPS Growth | Div | Yield |
|---|---|---|---|---|---|---|---|---|
| 2016-12-31 | 39,807.00 | 4,659.00 | €1.42 | 39.4 | 5.1 | 8% | €1.85 | 3.3% |
| 2017-12-31 | 40,122.00 | 6,521.00 | $0.88 | 63.9 | -1.3 | -48% | $1.89 | 3.4% |
| 2018-12-31 | 42,294.00 | 8,701.00 | $2.34 | 32.2 | 0.2 | 166% | $1.99 | 2.6% |
| 2019-12-31 | 46,840.00 | 11,464.00 | $3.84 | 23.7 | 0.4 | 64% | $2.26 | 2.5% |
| 2020-12-31 | 47,994.00 | 8,791.00 | $2.79 | 29.3 | -1.1 | -27% | $2.48 | 3.0% |
| Merck starts third phase clinical trial to evaluate Covid-19 treatment molnupiravir Sharecast News | 02 Sep |
|---|---|
| AstraZeneca, MSD prostate cancer drug gets China green light Sharecast News | 24 Jun |
| US government to spend $1.2bn on Merck Covid drug Sharecast News | 09 Jun |